Immunotech Laboratories, Inc. (IMMB) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IMMB representa a Immunotech Laboratories, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Immunotech Laboratories, Inc. (IMMB) Resumen de Asistencia Médica y Tuberías
Immunotech Laboratories, Inc. is a pharmaceutical company specializing in the development of proprietary proteins, notably ITV-1, for treating HIV/AIDS, Hepatitis C, and other immuno-related disorders. Operating as a subsidiary of Eco-Petroleum Solutions, Inc., the company focuses on modulating the immune system through its unique therapeutic vaccine.
Tesis de Inversión
Immunotech Laboratories, Inc. presents a highly speculative investment opportunity due to its focus on ITV-1, a proprietary protein aimed at treating HIV/AIDS and Hepatitis C. The company's potential hinges on the successful development and commercialization of ITV-1, which could address significant unmet needs in the treatment of these diseases. However, as a subsidiary of Eco-Petroleum Solutions, Inc., its financial performance and strategic direction are closely tied to its parent company. The company's small size and limited resources pose challenges to its ability to navigate the complex regulatory landscape and compete with larger pharmaceutical companies. With a negative P/E ratio of -0.23 and a beta of -77.02, the stock demonstrates high volatility and speculative interest. Investors should carefully consider the risks associated with investing in a small, OTC-traded pharmaceutical company with a limited product pipeline.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc. since June 14, 2017.
- The company's primary product is ITV-1, an immune therapeutic vaccine targeting HIV/AIDS and Hepatitis C.
- The company has a negative Price/Earnings ratio of -0.23, indicating it is not currently profitable.
- The company has a beta of -77.02, suggesting an inverse correlation to market movements and high volatility.
- Immunotech Laboratories, Inc. does not offer a dividend, reflecting its focus on reinvesting earnings into research and development.
Competidores y Pares
Fortalezas
- Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
- Operates as a subsidiary of Eco-Petroleum Solutions, Inc.
Debilidades
- Small size and limited resources.
- Dependence on a single product (ITV-1).
- Limited market presence.
- OTC market listing.
Catalizadores
- Upcoming: Clinical trial results for ITV-1 in HIV/AIDS and Hepatitis C (timeline: 12-18 months).
- Upcoming: Potential strategic partnerships with larger pharmaceutical companies (timeline: 6-12 months).
- Ongoing: Research and development efforts to expand the applications of ITV-1.
- Ongoing: Efforts to secure patent protection for ITV-1.
Riesgos
- Potential: Clinical trial failures or delays for ITV-1.
- Potential: Competition from larger pharmaceutical companies with greater resources.
- Potential: Regulatory hurdles and delays in obtaining approvals for ITV-1.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: OTC market listing and associated liquidity risks.
Oportunidades de crecimiento
- Expansion of ITV-1 Applications: Immunotech could explore expanding the applications of ITV-1 beyond HIV/AIDS and Hepatitis C to other immuno-related disorders. The market for immunomodulatory therapies is growing, driven by increasing understanding of immune system dysfunction in various diseases. Successful expansion could significantly increase the market opportunity for ITV-1, although it would require additional research and clinical trials. The timeline for this expansion is estimated at 3-5 years, contingent on regulatory approvals and clinical trial outcomes.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Immunotech with access to additional resources, expertise, and distribution channels. Collaborations could accelerate the development and commercialization of ITV-1 and expand its market reach. The timeline for establishing such partnerships is estimated at 1-2 years, depending on the attractiveness of ITV-1 to potential partners. This could provide a significant boost to Immunotech's growth prospects.
- Geographic Expansion: Expanding its geographic presence beyond the United States could open up new markets for ITV-1. HIV/AIDS and Hepatitis C are global health challenges, and there is significant demand for effective treatments in developing countries. Geographic expansion would require navigating different regulatory environments and establishing distribution networks. The timeline for this expansion is estimated at 2-4 years, depending on the specific target markets and regulatory requirements.
- Development of New Proprietary Proteins: Investing in the development of new proprietary proteins could diversify Immunotech's product pipeline and reduce its reliance on ITV-1. This would require significant investment in research and development, but it could create new revenue streams and enhance the company's long-term growth prospects. The timeline for developing new proprietary proteins is estimated at 3-5 years, depending on the complexity of the research and development process.
- Acquisition by a Larger Pharmaceutical Company: Immunotech could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its portfolio of immunomodulatory therapies. An acquisition would provide Immunotech with access to greater resources and expertise, and it could accelerate the development and commercialization of ITV-1. The timeline for a potential acquisition is uncertain, but it could occur within the next 1-3 years, depending on market conditions and the strategic priorities of potential acquirers.
Oportunidades
- Expansion of ITV-1 applications to other immuno-related disorders.
- Strategic partnerships with larger pharmaceutical companies.
- Geographic expansion to new markets.
- Development of new proprietary proteins.
Amenazas
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Patent expiration and generic competition.
- Changes in healthcare policies and reimbursement rates.
Ventajas competitivas
- Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
Acerca de IMMB
Immunotech Laboratories, Inc. was founded to develop and commercialize proprietary proteins aimed at treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. The company's primary focus is on its flagship compound, ITV-1 (immune therapeutic vaccine), which is a suspension of irreversible pepsin fraction designed to treat HIV/AIDS and Hepatitis C, as well as to modulate the immune system. ITV-1 represents the core of Immunotech's efforts to provide innovative solutions in the field of immune-related therapies. Headquartered in Monrovia, California, Immunotech operates as a subsidiary of Eco-Petroleum Solutions, Inc., since June 14, 2017. This acquisition has allowed Immunotech to continue its research and development activities under the umbrella of a larger entity. The company's strategy revolves around leveraging its proprietary protein technology to address significant unmet needs in the treatment of viral and immune-related diseases. Immunotech's small team is focused on advancing ITV-1 through various stages of development and exploring its potential applications in other immuno-related conditions. The company aims to establish itself as a key player in the development of novel immunomodulatory therapies.
Qué hacen
- Develop proprietary proteins for treating immuno-related disorders.
- Focus on the development of ITV-1 (immune therapeutic vaccine).
- Target HIV/AIDS and Hepatitis C with ITV-1.
- Modulate the immune system through their therapeutic vaccine.
- Conduct research and development activities to advance ITV-1.
- Operate as a subsidiary of Eco-Petroleum Solutions, Inc.
Modelo de Negocio
- Develop and commercialize proprietary proteins.
- Generate revenue through the sale of ITV-1.
- Focus on treating HIV/AIDS and Hepatitis C.
- Operate as a subsidiary of Eco-Petroleum Solutions, Inc.
Contexto de la Industria
Immunotech Laboratories, Inc. operates within the medical pharmaceutical industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for HIV/AIDS and Hepatitis C treatments is well-established but continues to evolve with the development of new therapies. Immunotech's focus on proprietary proteins and immune modulation places it in a niche segment of the market, competing with larger pharmaceutical companies that have broader product portfolios and greater resources. The company's success depends on its ability to differentiate ITV-1 and demonstrate its clinical efficacy and safety.
Clientes Clave
- Patients with HIV/AIDS.
- Patients with Hepatitis C.
- Healthcare providers treating immuno-related disorders.
Finanzas
Gráfico e información
Precio de la acción de Immunotech Laboratories, Inc. (IMMB): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para IMMB.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para IMMB.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para IMMB.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de IMMB en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Harry H. Zhabilov Jr. McS
CEO
Harry H. Zhabilov Jr. McS serves as the CEO of Immunotech Laboratories, Inc. His background includes experience in managing small teams and overseeing the development of pharmaceutical products. He has a McS degree. His leadership is focused on advancing the company's flagship compound, ITV-1, through the necessary regulatory and clinical milestones. Zhabilov's expertise is crucial in navigating the complex landscape of the pharmaceutical industry and driving the company's strategic initiatives.
Historial: Under Harry H. Zhabilov Jr.'s leadership, Immunotech Laboratories, Inc. has continued to focus on the development of ITV-1. His tenure has involved navigating the challenges of a small pharmaceutical company operating in a competitive market. Key decisions have included prioritizing research and development efforts and seeking strategic partnerships to support the company's growth. He manages a team of 4 employees.
Información del mercado OTC de IMMB
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immunotech Laboratories, Inc. may not meet the minimum financial standards or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may be subject to limited regulatory oversight and may not provide as much information to investors as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity due to OTC trading.
- Lack of regulatory oversight compared to major exchanges.
- Potential for higher price volatility.
- Uncertainty regarding financial reporting and disclosure.
- Dependence on a single product (ITV-1).
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the potential market for ITV-1.
- Understand the regulatory landscape and clinical trial risks.
- Review the company's patent protection and intellectual property.
- Monitor the company's news and press releases for updates.
- Consult with a financial advisor before investing.
- Focus on developing treatments for HIV/AIDS and Hepatitis C.
- Existence of a proprietary protein technology (ITV-1).
- Operation as a subsidiary of Eco-Petroleum Solutions, Inc.
- CEO with experience in managing pharmaceutical products.
Acciones de Immunotech Laboratories, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar IMMB?
Immunotech Laboratories, Inc. (IMMB) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Proprietary protein technology (ITV-1).. Riesgo principal a monitorear: Potential: Clinical trial failures or delays for ITV-1.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de IMMB?
IMMB actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de IMMB?
Los precios de IMMB se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre IMMB?
La cobertura de analistas para IMMB incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en IMMB?
Las categorías de riesgo para IMMB incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures or delays for ITV-1.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de IMMB?
La relación P/E para IMMB compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está IMMB sobrevalorada o infravalorada?
Determinar si Immunotech Laboratories, Inc. (IMMB) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de IMMB?
Immunotech Laboratories, Inc. (IMMB) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on limited publicly available data.
- OTC market stocks carry higher risk than exchange-listed stocks.
- Financial data may not be fully up-to-date.